Heather Ivy Society News

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention

https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention

Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. Apretude is given first as two initiation injections administered one month apart, and then every two months thereafter. Patients can either start their treatment with Apretude or take oral cabotegravir (Vocabria) for four weeks to assess how well they tolerate the drug.

Continue reading
214 Hits
0 Comments

World AIDS Day – 2020

World AIDS Day – 2020
World AIDS Day – 2020
Continue reading
378 Hits
0 Comments

PERSONALIZED FOR YOU

GET STARTED BY CONNECTING WITH US TODAY

 View Resources Join Discussions

CALL US: 844.884.9691

STAY IN THE KNOW
WITH OUR NEWSLETTER

© 2022 Heather Ivy Society. All rights reserved. Website developed by GoMe